Evaxion A (EVAX) Accounts Payables (2019 - 2025)
Evaxion A's (EVAX) quarterly Accounts Payables came in at $2.2 million in Q4 2025, down 26.35% YoY from $3.0 million in Q4 2024, and down 12.42% on a QoQ basis from $2.5 million in Q2 2025.
Evaxion A (EVAX) Accounts Payables (2019 - 2025) Analysis & Trends
Evaxion A (EVAX) has 7 years of Accounts Payables data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Accounts Payables fell 26.35% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 26.35% YoY) and the FY2025 annual result came in at $2.2 million, down 26.35% from the prior year.
- Accounts Payables slipped to $2.2 million in Q4 2025, from $2.5 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $3.4 million in Q1 2021 to a low of $538000.0 in Q3 2021.
- A 5-year average of $2.3 million and a median of $2.5 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 57.15% — and 2023, when it tumbled 30.91%.
- Tracing EVAX's Accounts Payables over 5 years: stood at $2.8 million in 2021, then declined by 26.79% to $2.1 million in 2022, then rose by 28.97% to $2.7 million in 2023, then climbed by 10.38% to $3.0 million in 2024, then slipped by 26.35% to $2.2 million in 2025.
- The last three Accounts Payables figures came in at $2.2 million (Q4 2025), $2.5 million (Q2 2025), and $3.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.19 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Jun 30, 2022 | 2.44 Mn |
| Mar 31, 2022 | 2.49 Mn |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 538,000.00 |
| Jun 30, 2021 | 1.55 Mn |
| Mar 31, 2021 | 3.41 Mn |
| Dec 31, 2020 | 3.67 Mn |
| Dec 31, 2019 | 646,000.00 |